Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1
Authors
Keywords
-
Journal
GUT
Volume 64, Issue 11, Pages 1824-1833
Publisher
BMJ
Online
2015-10-08
DOI
10.1136/gutjnl-2015-310421
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans
- (2015) L. I. Backus et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin
- (2015) Mitchell L Shiffman et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus
- (2015) Mehdi Najafzadeh et al. ANNALS OF INTERNAL MEDICINE
- Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States
- (2015) Jagpreet Chhatwal et al. ANNALS OF INTERNAL MEDICINE
- Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response
- (2015) Bryony Simmons et al. CLINICAL INFECTIOUS DISEASES
- Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
- (2015) Michael Charlton et al. GASTROENTEROLOGY
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
- (2015) Michael Charlton et al. GASTROENTEROLOGY
- Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study
- (2015) Laura Gragnani et al. HEPATOLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
- (2015) David Wyles et al. HEPATOLOGY
- Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed
- (2015) Stanislas Pol et al. HEPATOLOGY
- Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease
- (2015) Andrew J. Leidner et al. HEPATOLOGY
- Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
- (2015) HEPATOLOGY
- Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation
- (2015) Xavier Forns et al. HEPATOLOGY
- P0840 : Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: Interim analysis of a prospective, observational study
- (2015) S. Alqahtani et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4
- (2015) Christophe Moreno et al. JOURNAL OF HEPATOLOGY
- O002 : Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3
- (2015) G.R. Foster et al. JOURNAL OF HEPATOLOGY
- LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*
- (2015) S. Pol et al. JOURNAL OF HEPATOLOGY
- LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study
- (2015) P.J. Pockros et al. JOURNAL OF HEPATOLOGY
- O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens
- (2015) P. Krishnan et al. JOURNAL OF HEPATOLOGY
- From non-A, non-B hepatitis to hepatitis C virus cure
- (2015) Jean-Michel Pawlotsky et al. JOURNAL OF HEPATOLOGY
- O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
- (2015) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- EASL Recommendations on Treatment of Hepatitis C 2015
- (2015) JOURNAL OF HEPATOLOGY
- Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4
- (2015) Wahid Doss et al. JOURNAL OF HEPATOLOGY
- Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
- (2015) Anita Kohli et al. LANCET
- Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
- (2015) Christophe Hézode et al. LANCET
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
- (2015) Marc Bourlière et al. LANCET INFECTIOUS DISEASES
- Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial
- (2015) K Rajender Reddy et al. LANCET INFECTIOUS DISEASES
- Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
- (2015) Anita Kohli et al. LANCET INFECTIOUS DISEASES
- Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
- (2015) Laurent Mailly et al. NATURE BIOTECHNOLOGY
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) Susanna Naggie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) David L. Wyles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection
- (2015) Shanshan He et al. Science Translational Medicine
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
- (2014) A. Hill et al. CLINICAL INFECTIOUS DISEASES
- ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
- (2014) Pietro Andreone et al. GASTROENTEROLOGY
- Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
- (2014) Christophe Hézode et al. GUT
- Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
- (2014) Fei Xiao et al. GUT
- Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection
- (2014) Yao-Chun Hsu et al. GUT
- Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population
- (2014) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward)
- (2014) G. J. Dore et al. JOURNAL OF VIRAL HEPATITIS
- Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial
- (2014) Masao Omata et al. JOURNAL OF VIRAL HEPATITIS
- Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
- (2014) Christopher J L Murray et al. LANCET
- An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
- (2014) Paul Y. Kwo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C can be cured globally, but at what cost?
- (2014) A. Hill et al. SCIENCE
- Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
- (2013) James C. Sullivan et al. CLINICAL INFECTIOUS DISEASES
- Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
- (2013) Yaron Rotman et al. GUT
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- (2013) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Viral hepatitis and the Global Burden of Disease: a need to regroup
- (2013) G. S. Cooke et al. JOURNAL OF VIRAL HEPATITIS
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
- (2013) Benjamin Maasoumy et al. PLoS One
- New challenges in viral hepatitis
- (2012) David Thomas et al. GUT
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
- (2012) Christoph Welsch et al. GUT
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
- (2012) Khayriyyah Mohd Hanafiah et al. HEPATOLOGY
- Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense
- (2012) Alessio Aghemo et al. JOURNAL OF HEPATOLOGY
- A French prospective observational study of the treatment of chronic hepatitis C in drug abusers
- (2008) P. Chossegros et al. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation